tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Judah Frommer, 108 are a BUY (68.79%), 42 are a HOLD (26.75%), 7 are a SELL (4.46%).
Analyst Judah Frommer, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 65.33% that have a potential upside of 42.86% achieved within 272 days.
Judah Frommer’s has documented 325 price targets and ratings displayed on 37 stocks. The coverage is on Consumer Defensive, Consumer Cyclical, Healthcare sectors.
Most recent stock forecast was given on FDMT, 4D Molecular Therapeutics at 07-Nov-2025.
Analyst best performing recommendations are on ACLX (ARCELLX).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 5/15/2023. The price target of $151 was fulfilled within 1 day with a profit of $6.19 (3.94%) receiving and performance score of 39.38.
Average potential price target upside
Analyst name
Rating
Rating initiation date
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
Since 03-Nov-2017
$145
$17.3 (13.55%)
$125
16 days ago
(19-Dec-2025)
22/31 (70.97%)
$17.16 (13.42%)
349
Hold
Since 26-Nov-2021
$130
$2.3 (1.80%)
$105
27 days ago
(08-Dec-2025)
13/13 (100%)
$9.67 (8.04%)
90
Buy
Since 10-Jan-2018
$130
$2.3 (1.80%)
$125
1 months ago
(04-Dec-2025)
12/17 (70.59%)
$17.08 (15.13%)
349
Buy
Since 29-Aug-2025
$135
$7.3 (5.72%)
$130
1 months ago
(04-Dec-2025)
21/40 (52.5%)
$22.08 (19.55%)
95
Sell
Since 27-Aug-2021
$85
$-42.7 (-33.44%)
$75
1 months ago
(04-Dec-2025)
19/21 (90.48%)
$-27.92 (-24.73%)
238
Which stock is Judah Frommer is most bullish on?
What Year was the first public recommendation made by Judah Frommer?
